Twin Peaks Wealth Advisors’s Gilead Sciences GILD Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$236K	Buy	1,693 +44	+3%	+$6.16K	0.06%	166
2025 Q4	$250K	Buy	+1,649	New	+$200K	0.07%	156
2025 Q3	–	Sell	-1,489	Closed	-$179K	–	938
2025 Q2	$179K	Buy	+1,489	New	+$158K	0.06%	165
2025 Q1	–	Sell	-2,480	Closed	-$229K	–	145
2024 Q4	$229K	Sell	2,480 -405	-14%	-$36.5K	0.1%	129
2024 Q3	$242K	Buy	+2,885	New	+$220K	0.11%	113
2024 Q2	–	Sell	-3,000	Closed	-$220K	–	131
2024 Q1	$220K	Sell	3,000 -197	-6%	-$15.1K	0.12%	120
2023 Q4	$259K	Buy	+3,197	New	+$249K	0.17%	104

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Twin Peaks Wealth Advisors's GILD Position: Q1 2026 in Review

Twin Peaks Wealth Advisors increased its Gilead Sciences (GILD) stake by 2.7% in Q1 2026, buying an estimated $6.16K and bringing the position to 1,693 shares worth $236K. The position accounts for 0.06% of the portfolio, ranked #166.

Twin Peaks Wealth Advisors first reported a position in GILD in Q4 2023 and has held it in 7 quarters since. The position peaked at $259K in Q4 2023. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Twin Peaks Wealth Advisors held 1,693 shares of Gilead Sciences worth $236K as of Q1 2026.
Twin Peaks Wealth Advisors bought 44 Gilead Sciences shares in Q1 2026, an estimated $6.16K.
Gilead Sciences made up 0.06% of Twin Peaks Wealth Advisors's portfolio in Q1 2026, its #166 holding.
Twin Peaks Wealth Advisors first reported a position in Gilead Sciences in Q4 2023 and has held it in 7 quarters since.
Twin Peaks Wealth Advisors's Gilead Sciences position peaked at $259K in Q4 2023.
2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q1 2026, filed 8 May 2026.